Intra-Cellular Therapies (ITCI) PT Raised to $75 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Intra-Cellular Therapies (ITCI) PT Raised to $95 at Leerink Partners
September 18, 2015 6:42 AM EDTLeerink Partners analyst Seamus Fernandez reiterated an Outperform rating and sharply raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $95.00 (from $36.00).
"Based on the positive Phase III results announced on Wednesday, we are increasing our probability of success (POS) for ITI-007 in... More
Intra-Cellular Therapies (ITCI) Price Target Raised to Street-High $95 at Guggenheim
September 17, 2015 9:03 AM EDTGuggenheim maintained a Buy rating on Intra-Cellular Therapies (NASDAQ: ITCI) and raised its price target to $95.00 (from $36.00). The price target is a Street-high.
For an analyst ratings summary and ratings history on Intra-Cellular Therapies... More
Leerink Partners Remains Bullish on Intra-Cellular Therapies (ITCI) Following Positive ITI-007 Results
September 16, 2015 2:10 PM EDTLeerink Partners reiterated an Outperform rating and $39.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI) following the announced positive Ph3 results of ITI-007. Analyst Seamus Fernandez believes that the data clearly validates the 60 mg ITI-007 as an attractive treatment option for schizophrenia and will increase the likelihood of success of the overall program.... More
RBC Capital Comments on Intra-Cellular's (ITCI) Positive ITI-007 Phase 3 Study
September 16, 2015 8:11 AM EDTRBC Capital analyst Adnan Butt commented on Intra-Cellular Therapies (NASDAQ: ITCI) following the release of first phase III ITI-007 study results in schizophrenia, which meet its primary endpoint. Butt, who has an Outperform rating on the stock with a price target of $42, made note of the statistically significant benefit and clean safety, though he pointed out that the bull-bear debate continues.
"The first Phase III study met the primary efficacy endpoint of total PANSS and demonstrated potentially... More
Intra-Cellular Therapies' (ITCI) Phase 3 Trial of ITI-007 in Schizophrenia Met Primary Endpoint
September 16, 2015 6:45 AM EDTIntra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced positive results from the first Phase 3 clinical trial of ITI-007 for the treatment of patients with schizophrenia. In this trial, once-daily ITI-007 60 mg met the primary endpoint and demonstrated antipsychotic efficacy with statistically significant superiority over placebo at Week 4 (study endpoint) as measured by the change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score (p=0.022). Moreover, ITI-007 60 mg showed significant antipsychotic efficacy as early as week 1, which was maintained at every time point throughout the entire study. ITI-007 60 mg also met the key secondary endpoint... More
